Although the current technical state of the Xpert MTB/RIF assay prevents the complete retirement of smear microscopy, we hope that future technological advances in rapid molecular methods, including the Xpert MTB/RIF assay, will allow full replacement of smear microscopy for the diagnosis of mycobacterial diseases. ■

Author disclosures are available with the text of this letter at www.atsjournals.org.

Hyun-Woo Choi, M.D., Ph.D.*
Ju-Hyeon Shin, M.D.*
Seung-Jung Kee, M.D., Ph.D.‡
Yong-Soo Kwon, M.D., Ph.D.
Taeo Ma, M.D.
Hyun-Seung Lee, M.D., Ph.D.
Sejong Chun, M.D.
Eun Jeong Won, M.D., Ph.D.
Jong-Hee Shin, M.D., Ph.D.
Chonnam National University Medical School
Gwangju, Republic of Korea

and

Chonnam National University Hospital
Gwangju, Republic of Korea

ORCID IDs: 0000-0002-9438-1603 (H.-W.C.); 0000-0002-6270-9205 (J.-H.S.); 0000-0001-9708-5837 (S.-J.K.); 0000-0001-5121-4488 (Y.-S.K.); 0000-0002-3972-8766 (T.M.); 0000-0003-4590-4989 (H.-S.L.); 0000-0001-7462-5802 (S.C.); 0000-0002-8750-4257 (E.J.W.); 0000-0001-9593-476X (J.-H.S.).

*These authors contributed equally to this work and are joint first authors.
‡Corresponding author (e-mail: sjkee@jnu.ac.kr).

References

1. Lee HS, Kee SJ, Shin JH, Kwon YS, Chun S, Lee JH, *et al*. Xpert MTB/RIF assay as a substitute for smear microscopy in an intermediate-burden setting. *Am J Respir Crit Care Med* 2019;199: 784–794.
2. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, *et al*.; ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Disease Society of America. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. *Am J Respir Crit Care Med* 2007;175: 367–416. [Published erratum appears in Am J Respir Crit Care Med 175:744–745.]
3. Kwon YS, Koh WJ, Daley CL. Treatment of *Mycobacterium avium* complex pulmonary disease. *Tuberc Respir Dis (Seoul)* 2019;82:15–26.
4. Philley JV, DeGroote MA, Honda JR, Chan MM, Kasperbauer S, Walter ND, *et al*. Treatment of non-tuberculous mycobacterial lung disease. *Curr Treat Options Infect Dis* 2016;8:275–296.
5. Friedrich SO, Rachow A, Saathoff E, Singh K, Mangu CD, Dawson R, *et al*.; Pan African Consortium for the Evaluation of Anti-tuberculosis Antibiotics (PanACEA). Assessment of the sensitivity and specificity of Xpert MTB/RIF assay as an early sputum biomarker of response to tuberculosis treatment. *Lancet Respir Med* 2013;1:462–470.
6. Sali M, De Maio F, Caccuri F, Campilongo F, Sanguinetti M, Fiorentini S, *et al*. Multicenter evaluation of Anyplex Plus MTB/NTM MDR-TB assay for rapid detection of *Mycobacterium tuberculosis* complex and multidrug-resistant isolates in pulmonary and extrapulmonary specimens. *J Clin Microbiol* 2016;54:59–63.

Erratum: XBP1S Regulates MUC5B in a Promoter Variant–Dependent Pathway in Idiopathic Pulmonary Fibrosis Airway Epithelia

Because of a typesetting error, the expression "air–liquid interface" was incorrectly replaced with "acute lung injury" in the article by Chen and colleagues (1), published in the July 15, 2019, issue of the *Journal*. This error appears in the legends to Figures 1, 2, and 7. ■

References

1. Chen G, Ribeiro CMP, Sun L, Okuda K, Kato T, Gilmore RC, Martino MB, Dang H, Abzhanova A, Lin JM, Hull-Ryde EA, Volmer AS, Randell SH, Livraghi-Butrico A, Deng Y, Scherer PE, Stripp BR, O'Neal WK, Boucher RC. XBP1S regulates MUC5B in a promoter variant–dependent pathway in idiopathic pulmonary fibrosis airway epithelia. *Am J Respir Crit Care Med* 2019;200:220–234.